Skip to main content
. Author manuscript; available in PMC: 2014 Sep 19.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2
Trial name or title RIS-INT-45
Methods Allocation: random, using a central randomisation procedure.
Blindness.: double, no further details.
Duration: 8 weeks.
Design: parallel.
Location: multicentre.
Participants Diagnosis: (DSM-IV) schizophrenia, PANSS between 60 and 120. N=not reported.
Sex: not reported.
Age: 18-65 years.
History: duration ill not reported., age at onset not reported.
Setting: in- and outpatient.
Interventions

  1. Olanzapine: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported.

  2. Risperidone: fixed/flexible dose: not reported. Allowed dose range: not reported. Mean dose: not reported. N=not reported
Outcomes Efficacy.
Cognitive functioning.
Adverse effects: Sleepiness, weight gain, safety.
Starting date 1 April 1997
Contact information Professor Michael Reveley
Department of Psychiatry
Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
PO BOX 65
LE2 7LX
United Kingdom
Telephone: 0116 252 3242
Notes